This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
Expected survival time of ≥3 months.
Refractory moderate - to - severe active systemic sclerosis that has failed standard treatment or lacks effective therapeutic options.
Meets the requirements for liver and kidney function, as well as cardiopulmonary function.
A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening.
Positive results in virology/syphilis tests.
Severe cardiac diseases or unstable systemic diseases.
Presence of active or uncontrollable infections requiring systemic treatment, or evidence of central nervous system invasion.